Idiopathic Pulmonary Fibrosis Management Market Report 2023: R&D Consistency Drives Sector Growth

During the forecast period 2023 to 2033, the Idiopathic pulmonary fibrosis management market is expected to grow at a value of 1.5% CAGR, according to Future Market Insights. By the year 2033, the global market for Idiopathic pulmonary fibrosis management is expected to rise up to a market valuation of US$ 3649.90 Million. Growth of the market can be attributed to rising cases of idiopathic pulmonary fibrosis mong middle aged men.

Several diagnostic methods exist for identifying IPF, and guidelines for diagnosis have been established. Tests such as pulmonary function tests are used to evaluate restrictive lung disease, which is indicated by decreased lung volume (specifically, reduced forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity.

Furthermore, North America and Europe are two major regions contributing to the growth of the Idiopathic pulmonary fibrosis management market. This is owing to the high prevalence of the ailment in regions such as the Unites States of America and Germany. In addition, availability of various drugs along with innovative medication is shaping the landscape for the Idiopathic pulmonary fibrosis management market.

Key Takeaways from the Market Study

  • Idiopathic pulmonary fibrosis management market is expected to grow at a value of 1.5% CAGR in the forecast period 2023 to 2033.
  • By distribution channel, retail pharmacies are expected to possess 40% market share for Idiopathic pulmonary fibrosis management market in 2023.
  • North America is expected to possess 45% market share for Idiopathic pulmonary fibrosis management market in 2023.
  • Europe is expected to hold 40% market share for Idiopathic pulmonary fibrosis management market in 2023.

“The presence of a wide range of drugs, as well as new and innovative medications, is influencing the market for managing Idiopathic pulmonary fibrosis.” states an FMI analyst

Competitive Landscape

Key players in the idiopathic pulmonary fibrosis management market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova Inc, BristoltoMyers Squibb Company, Galapagos NV, HoffmanntoLa Roche AG, Neopharm Group, Galecto Biotech, Pfizer Inc, Johnson & Johnson Services, Inc, AstraZeneca

Read More@ https://www.futuremarketinsights.com/reports/idiopathic-pulmonary-fibrosis-management-market

Key Segments Profiled in the Idiopathic Pulmonary Fibrosis Management Industry Survey

Drug Class:

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato1b
  • Others

Treatment:

  • Oxygen Therapy
  • Lung Transplant
  • Others

Route of Administration:

  • Oral
  • Injectable

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Comments

Post a Comment

Popular posts from this blog

Portable Oxygen Concentrators Market | Innovative and Technological Advancement

Image
The global  portable oxygen concentrators market  is anticipated to witness lucrative growth opportunities over the forecast period from 2022 and 2032, with a phenomenal CAGR of 10.1%. The market is expected to enjoy a valuation of US$ 1.9 Billion by the end of the year 2022 and surpass a projection of US$ 5.0 Billion by the year 2032. According to the Future Market Insights historical analysis, the pulse flows portable oxygen concentrators were leading the market with a share of about 67.7% in the year 2021, within the global market. In the year 2021, the market value for portable oxygen concentrators was around 54.8% of the overall US$ 3.5 Billion of the global oxygen concentrators market. Portable oxygen concentrators supply oxygen to those patients who are suffering from respiratory diseases such as chronic obstructive pulmonary disease. In this process, nitrogen and oxygen are separated from the air in the environment with the help of the concentrator which then discards ...
Read more

Pediatric Clinical Trials Market size is set to Grow at a Remarkable Pace by 2032

Image
During the forecast period 2022 to 2032, the global pediatric clinical trials market  is expected to grow at a value of 5.3%, according to Future Market Insights. In 2022, this market was predicted to have a global valuation of US$ 15.8 Billion, and is expected to reach a sum of US$ 26.47 Billion by 2032. The market is going to face increasing demand owing to the increase of pediatric chronic and genetic diseases all across the world. The growing need for novel vaccines and biopharmaceuticals to treat infectious diseases such as measles, polio, tuberculosis, rubella, influenza, mumps, whooping cough, malaria, chickenpox, and staphylococcus pharyngitis is expected to drive market growth. At the same time, diabetes is a big worry among today's children. The market is being driven by rising parental awareness of children clinical trials for severe infections and chronic diseases, as well as a large number of CROs doing pediatric research. In 2021, the onc...
Read more

Helicobacter Pylori Infections Treatment Market Research and Analysis 2023 to 2033

Image
The global helicobacter pylori infections treatment market is predicted to reach US$ 638.3 Million in 2023, with a compound annual growth rate (CAGR) of 7.04% anticipated from 2023 to 2033, reaching US$ 1,260 Million. The spread of such infections can be attributed to a number of factors, including a lack of adequate water supply, poor sanitation, a large population, and poor personal hygiene. One of the factors influencing the Helicobacter pylori diagnostics market's growth is increased awareness of H. pylori infections in the cohort. Antibiotic availability and affordability, as well as quicker processing times, will boost antibiotic use and the need for pre and post-surveillance tests. Furthermore, rising H. pylori infection rates, the need for early symptom diagnosis, and technological advances in diagnostic methods are expected to fuel overall growth over the forecast period. The key drivers of the industry are the increasing prevalence of communicable diseases and rising pub...
Read more